摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(5-甲基-1,2,4-恶二唑-3-基)苯甲酸 | 1372190-03-8

中文名称
2-(5-甲基-1,2,4-恶二唑-3-基)苯甲酸
中文别名
——
英文名称
2-(5-methyl-1,2,4-oxadiazol-3-yl)benzoic acid
英文别名
2-(5-Methyl-1,2,4-oxadiazol-3-yl)benzoic acid
2-(5-甲基-1,2,4-恶二唑-3-基)苯甲酸化学式
CAS
1372190-03-8
化学式
C10H8N2O3
mdl
——
分子量
204.185
InChiKey
FGACRIAAIIXTOO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    76.2
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] NOVEL N-[(PYRIMIDINYLOXY)PROPANYL]BENZAMIDES<br/>[FR] NOUVEAUX N-[(HÉTÉROARYLOXY)PROPANYL]HÉTÉROARYL CARBOXAMIDES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2017178338A1
    公开(公告)日:2017-10-19
    This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5 have meanings given in the description.
    这项发明涉及到式(I)的化合物,其制备方法,含有它们的药物组合物以及它们在治疗与促觉醒素亚型1受体相关的疾病中的应用。Ar,R1,R2,R3,R4,R5的含义如描述中所示。
  • [EN] NOVEL N-[(PYRAZINYLOXY)PROPANYL]BENZAMIDES<br/>[FR] NOUVEAUX N-[(PYRAZINYLOXY)PROPANYL]BENZAMIDES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2017178339A1
    公开(公告)日:2017-10-19
    This invention relates to compounds of formula (I) a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2 and R3 have meanings given in the description.
    这项发明涉及式(I)的化合物,其制备方法,含有它们的药物组合物以及它们在治疗与促觉肽亚型1受体相关的疾病中的应用。Ar、R1、R2和R3的含义如描述中所示。
  • [EN] NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES<br/>[FR] NOUVEAUX N-[(PYRIMIDINYLAMINO)PROPANYL]- ET N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2017178341A1
    公开(公告)日:2017-10-19
    The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    本发明涉及新颖的N-[(嘧啶基)丙基]-和N-[(吡嗪基)丙基]芳基甲酰胺生物,其制备方法,含有它们的药物组合物以及它们在治疗中的应用,特别是在与促觉醒素亚型1受体有关的疾病的治疗或预防中的应用。
  • HETEROCYCLIC COMPOUNDS
    申请人:Ishichi Yuji
    公开号:US20120088748A1
    公开(公告)日:2012-04-12
    Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.
    提供的是一种具有单胺再摄取抑制活性的化合物,其化学式表示为(I),其中环A是一个可选择取代的6元芳香环,环B是环A上的取代基可选择地与环A一起形成一个可选择取代的9或10元芳香融合环,其他符号如规范中定义的那样,或其盐。
  • 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS
    申请人:Kuduk Scott D.
    公开号:US20130102619A1
    公开(公告)日:2013-04-25
    The present invention is directed to 2-pyridyloxy-4-nitrile compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyl-oxy-4-nitrile compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及2-吡啶基-4-腈基化合物,其是促进睡眠荷尔蒙受体的拮抗剂。本发明还涉及使用本文所述的2-吡啶基-4-腈基化合物治疗或预防神经和精神障碍和疾病,这些疾病涉及到促进睡眠荷尔蒙受体。本发明还涉及包含这些化合物的制药组合物。本发明还涉及使用这些制药组合物预防或治疗涉及促进睡眠荷尔蒙受体的疾病。
查看更多